Increased Survival after Treatment of Canine Hemangiosarcoma with Fenofibrate

International Journal of Veterinary Science and Research

Case Report

Abstract
Hemangiosarcoma (HSA) is a common and highly metastatic tumor that affects predominantly large-breed dogs. The median survival time for dogs diagnosed with splenic HSA without adjuvant chemotherapy after surgery is 86 days. Fenofibrate is an FDA-approved drug commonly utilized to treat high cholesterol and high triglyceride levels in humans. However, fenofibrate has also been shown to possess anti-proliferative and anti-metastatic properties against several aggressive and highly metastatic tumors in vitro and in small animal models. We report a case of a 6.5-year-old dog diagnosed with a splenic hemangiosarcoma and treated solely with micronized fenofibrate, administered orally once a day following splenectomy. The dog survived for over 26 months (804 days) after initial diagnosis without signs of adverse effects due to fenofibrate treatment.

http://www.peertechz.com/Veterinary-Science-Research/pdf/IJVSR-1-103.pdf

Comments

Popular posts from this blog

Peertechz is not Predatory Open Access Publisher

The prevention and cure research of emergency intervention therapy of balloon occlusion of LAD occurring reperfusion arrhythmia

Case Report: Reynolds Syndrome